Pfizer to acquire migraine firm for over USD 11bn

US-based Pfizer is prepared to pay as much as USD 11.6bn to buy Biohaven Pharmaceuticals and its approved migraine therapy.
Photo: Dado Ruvic/REUTERS / X02714
Photo: Dado Ruvic/REUTERS / X02714
by Benjamin Werner Christensen, translated by daniel pedersen

On Tuesday, Pfizer has announced its intention to acquire Biohaven Pharmaceuticals, agreeing to pay USD 148.5 per share in cash, which equals to a whopping price tag of USD 11.6bn, a company press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading